Cargando…
Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the prese...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162540/ https://www.ncbi.nlm.nih.gov/pubmed/30177612 http://dx.doi.org/10.3390/cancers10090304 |
_version_ | 1783359170688319488 |
---|---|
author | Rai, Shinya Tanaka, Hirokazu Fujimoto, Ko Kumode, Takahiro Inoue, Hiroaki Taniguchi, Yasuhiro Morita, Yasuyoshi Espinoza, J. Luis Tatsumi, Yoichi Ashida, Takashi Matsuoka, Ryota Kikuti, Yukie Yara Nakamura, Naoya Matsumura, Itaru |
author_facet | Rai, Shinya Tanaka, Hirokazu Fujimoto, Ko Kumode, Takahiro Inoue, Hiroaki Taniguchi, Yasuhiro Morita, Yasuyoshi Espinoza, J. Luis Tatsumi, Yoichi Ashida, Takashi Matsuoka, Ryota Kikuti, Yukie Yara Nakamura, Naoya Matsumura, Itaru |
author_sort | Rai, Shinya |
collection | PubMed |
description | A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the presence of typical Hodgkin/Reed-Sternberg (HRS) cells, surrounded by T-lymphocytes and CLL cells. Sequencing analysis of the germline complementary determining region 3 (CDR3) region of the immunoglobulin heavy chain (IGH) gene showed that the Hodgkin/Reed-Sternberg cells were clonally unrelated to the preexisting CLL cells and the HRS cells were composed of five different clones, leading to the molecular diagnosis of de novo lymphocyte-rich classic Hodgkin lymphoproliferative diseases (LPDs) with small lymphocytic lymphoma (SLL). As the initial treatment was neither effective for classic Hodgkin LPDs nor for SLL, Bendamustine, Rituximab (BR) was started and complete remission was achieved, which has continued for more than one year so far. BR may be a good therapeutic option for both entities without causing hematological toxicity. |
format | Online Article Text |
id | pubmed-6162540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61625402018-10-02 Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab Rai, Shinya Tanaka, Hirokazu Fujimoto, Ko Kumode, Takahiro Inoue, Hiroaki Taniguchi, Yasuhiro Morita, Yasuyoshi Espinoza, J. Luis Tatsumi, Yoichi Ashida, Takashi Matsuoka, Ryota Kikuti, Yukie Yara Nakamura, Naoya Matsumura, Itaru Cancers (Basel) Case Report A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the presence of typical Hodgkin/Reed-Sternberg (HRS) cells, surrounded by T-lymphocytes and CLL cells. Sequencing analysis of the germline complementary determining region 3 (CDR3) region of the immunoglobulin heavy chain (IGH) gene showed that the Hodgkin/Reed-Sternberg cells were clonally unrelated to the preexisting CLL cells and the HRS cells were composed of five different clones, leading to the molecular diagnosis of de novo lymphocyte-rich classic Hodgkin lymphoproliferative diseases (LPDs) with small lymphocytic lymphoma (SLL). As the initial treatment was neither effective for classic Hodgkin LPDs nor for SLL, Bendamustine, Rituximab (BR) was started and complete remission was achieved, which has continued for more than one year so far. BR may be a good therapeutic option for both entities without causing hematological toxicity. MDPI 2018-09-03 /pmc/articles/PMC6162540/ /pubmed/30177612 http://dx.doi.org/10.3390/cancers10090304 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Rai, Shinya Tanaka, Hirokazu Fujimoto, Ko Kumode, Takahiro Inoue, Hiroaki Taniguchi, Yasuhiro Morita, Yasuyoshi Espinoza, J. Luis Tatsumi, Yoichi Ashida, Takashi Matsuoka, Ryota Kikuti, Yukie Yara Nakamura, Naoya Matsumura, Itaru Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab |
title | Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab |
title_full | Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab |
title_fullStr | Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab |
title_full_unstemmed | Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab |
title_short | Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab |
title_sort | classic hodgkin lymphoproliferative diseases clonally unrelated to b-chronic lymphocytic leukemia successfully treated with bendamustine plus rituximab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162540/ https://www.ncbi.nlm.nih.gov/pubmed/30177612 http://dx.doi.org/10.3390/cancers10090304 |
work_keys_str_mv | AT raishinya classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT tanakahirokazu classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT fujimotoko classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT kumodetakahiro classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT inouehiroaki classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT taniguchiyasuhiro classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT moritayasuyoshi classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT espinozajluis classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT tatsumiyoichi classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT ashidatakashi classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT matsuokaryota classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT kikutiyukieyara classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT nakamuranaoya classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab AT matsumuraitaru classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab |